Page last updated: 2024-08-23
paclitaxel and xct790
paclitaxel has been researched along with xct790 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kataoka, H; Kitawaki, J; Kokabu, T; Matsushima, H; Mori, T; Tarumi, Y; Yoriki, K | 1 |
Other Studies
1 other study(ies) available for paclitaxel and xct790
| Article | Year |
|---|---|
Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endometrial Neoplasms; ERRalpha Estrogen-Related Receptor; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred BALB C; Nitriles; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Transcription, Genetic; Tubulin; Xenograft Model Antitumor Assays | 2019 |